United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glenmark pharmaceuticals (europe) ltd. - atovaquone 250 mg; proguanil hydrochloride 100 mg - film-coated tablet - 250 mg - 100 mg - atovaquone 250 mg; proguanil hydrochloride 100 mg - proguanil, combinations

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 60,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 90,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 120,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - inhaler - see ingredients - each actuation delivers salbutamol sulphate 100,0 ug

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - #n/a - not indicated - none

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - infusion - not indicated - none

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - infusion - not indicated - none

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age. esomeprazole magnesium delayed-release capsules delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. pediatric patients 12 years to 17 years of age esomeprazole magnes